AstraZeneca in drive to slash costs Hostile environment prompts root and branch review. Exanta unlikely to win US approval in near future. By Stephen Foley. AstraZeneca, the UK #39;s number two pharmaceuticals company, has launched a  quot;root and branch  

Which of the following sections of a newspaper would this article likely appear in? World News, Sports, Business, or Science and Technology? 